Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Teva Strengthens Respiratory Franchise

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
Company has entered into a definitive agreement to acquire MicroDose Therapeutx.

Teva Pharmaceutical Industries Ltd. has announced that it has entered into a definitive agreement to acquire MicroDose Therapeutx, a privately-held pharmaceutical and drug delivery company focused on inhalation technologies and products for lung diseases and infections with the potential to dramatically improve efficacy and patient compliance.

With the addition of MicroDose’s technologies and products, Teva is taking a significant step toward expanding its respiratory pipeline.

Teva will now have access to MicroDose’s proprietary technology including its multi-dose dry powder nebulizer device, which requires no preparation and can be administered in under 30 seconds.

MicroDose’s current pipeline is anchored by MDT-637 for respiratory syncytial virus (RSV) - an inhaled, low dose, small molecule, fusion inhibitor which prevents viral replication, delivered via MicroDose’s technology.

“I am thrilled that Teva can now count the exciting MicroDose products and technologies amongst our growing respiratory portfolio. The MicroDose platform is both simple and attractive, and their addition will help us to address the unmet needs of the youngest and oldest patients, who have a requirement for a better way of taking the medicines they rely upon,” stated Michael Hayden, President, Teva Global R&D, and Chief Scientific Officer.

Under the terms of the deal, Teva will acquire all of MicroDose’s outstanding shares for a payment at closing of $40 million, additional payments of up to $125 million upon achievement of regulatory and development milestones, plus sales-based milestones and tiered royalty payments upon commercialization of MDT-637 and an earlier stage Asthma/COPD medicine.

Anand V. Gumaste, President, CEO and Chairman of MicroDose, stated, “We believe this agreement provides a unique opportunity to advance MicroDose’s platform technology and development programs for the greatest benefit of patients. Teva has a strong and growing franchise in respiratory diseases, with extensive experience in both delivery mechanisms and novel therapeutic modalities. Teva also has a worldwide market presence and leading global supply chain.”

Stifel acted as exclusive financial advisor to MicroDose Therapeutx in this transaction.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Teva, Regeneron Announce Fasinumab Collaboration
Teva and Regeneron's global collaboration to develop and commercialize Fasinumab, an investigational NGF antibody for chronic pain.
Wednesday, September 21, 2016
Teva, AbCellera Launch Collaboration
Agreement further supports Teva’s novel biologics development program.
Wednesday, February 03, 2016
Teva, Takeda Collaborate
Teva Pharmaceutical Industries and Takeda Pharmaceutical Company Limited have announced that the two companies have entered into a definitive agreement to establish an unprecedented partnership in Japan.
Wednesday, December 02, 2015
Teva Acquires Rimsa
Strategic move enhances Teva’s presence in Mexico, the second largest market in Latin America and a major emerging market.
Friday, October 09, 2015
Teva to Acquire Gecko Health Innovations
Teva Pharmaceutical Industries Ltd., and Gecko Health Innovations, Inc have announced that they have entered into a definitive agreement in which Teva will acquire Gecko Health Innovations.
Thursday, October 01, 2015
Teva Announces FDA Acceptance of NDA for SD-809 for Huntington Disease Treatment
The FDA designates orphan status to drugs and biologics that are intended for the treatment of rare diseases affecting fewer than 200,000 people in the U.S.
Monday, August 17, 2015
Teva and Microchips Biotech Announce Partnership
Promising innovative technology offers potential across therapeutic areas and disease states.
Thursday, June 25, 2015
Teva Reinforces Leadership Position in CNS with Acquisition of Auspex
All-cash transaction with enterprise value of $3.2 billion.
Thursday, April 02, 2015
Teva to Acquire Labrys Biologics, Inc.
Novel migraine prophylaxis treatment adds significant new dimension to Teva’s growing pain care franchise.
Thursday, June 05, 2014
Teva Expands CNS Specialty Business with Acquisition of NuPathe
Teva will acquire NuPathe Inc. for $3.65 per share in cash.
Tuesday, January 28, 2014
Teva and Lonza Announce Mutual Decision to Discontinue Biologics Joint Venture
Teva to pursue its biologics strategy to create a balanced portfolio of biosimilars, biobetters and innovative biologics.
Friday, July 26, 2013
Teva Announces Progress of Biologic Investigational Drugs Evaluated to Treat Neutropenia in Breast Cancer Patients Undergoing Chemotherapy
Clinical results for Lipegfilgrastim and Balugrastim highlighted at oncology conference.
Tuesday, July 03, 2012
Teva Sees Limited Competition in Biosimilar Market
The company expects the fledgling market for so-called biosimilar drugs to be big, but the cost and complexity of developing them will limit competition, company executives said.
Monday, January 16, 2012
Dr. Rob Koremans to succeed Dr. Gerard van Odijk as President and CEO of Teva Europe
Dr. Koremans joins Teva after serving as CEO for Zentiva and most recently Senior Vice President Generic Strategy and Development at Sanofi-Aventis.
Friday, December 23, 2011
Teva Announces Drug Development Investment in Cocrystal Discovery Inc.
Cocrystal Discovery Inc. will initially develop an antiviral drug targeting the polymerase enzyme of the Hepatitis C virus for Teva.
Friday, September 23, 2011
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Biological Link between the Gut Microbiome and Parkinson’s Disease
The findings suggest that targeting the gut microbiome may provide a new approach for diagnosing and treating Parkinson’s disease.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Genetic Links to Brain Cancer Cell Growth
Researchers discover clues to tumour behaviour from genetic differences between brain cancer cells and normal tissue cells.
RNAi Activated in Response to Influenza
Discovery could lead to better ways of combating serious infections, including Ebola and Zika.
Allen Institute Releases Gene Edited Human Stem Cell Lines
The Allen Cell Collection, a publicly available collection of gene edited pluripotent stem cells, has been made available by the Allen Institute.
Inspiring Futuristic Innovation: Brain ‘Organoids’
Scientists create artificial brains, providing an advanced model for studying brain tumour development.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!